Abstract:Craniopharyngiomas are rare malignancies of dysembryogenic origin, involving the sellar and parasellar areas. These low-grade, epithelial tumors account for two main histological patterns (adamantinomatous craniopharyngioma and papillary craniopharyngioma), which differ in epidemiology, pathogenesis, and histomorphological appearance. Adamantinomatous craniopharyngiomas typically show a bimodal age distribution (5-15 years and 45-60 years), while papillary craniopharyngiomas are limited to adult patients, especially in the fifth and sixth decades of life. Recently, craniopharyngioma histological subtypes have been demonstrated to harbor distinct biomolecular signatures. Somatic mutations in CTNNB1 gene encoding β-catenin have been exclusively detected in adamantinomatous craniopharyngiomas, which predominantly manifest as cystic lesions, while papillary craniopharyngiomas are driven by BRAF V600E mutations in up to 95% of cases and are typically solid masses. Despite the benign histological nature (grade I according to the World Health Organization classification), craniopharyngiomas may heavily affect long-term survival and quality of life, due to their growth pattern in a critical region for the presence of eloquent neurovascular structures and possible neurological sequelae following their treatment. Clinical manifestations are mostly related to the involvement of hypothalamic-pituitary axis, optic pathways, ventricular system, and major blood vessels of the circle of Willis. Symptoms and signs referable to intracranial hypertension, visual disturbance, and endocrine deficiencies should promptly raise the clinical suspicion for sellar and suprasellar pathologies, advocating further neuroimaging investigations, especially brain MRI. The optimal therapeutic management of craniopharyngiomas is still a matter of debate. Over the last decades, the surgical strategy for craniopharyngiomas, especially in younger patients, has shifted from the aggressive attempt of radical resection to a more conservative and individualized approach via a planned subtotal resection followed by adjuvant radiotherapy, aimed at preserving functional outcomes and minimizing surgery-related morbidity. Whenever gross total removal is not safely feasible, adjuvant radiotherapy (RT) and stereotactic radiosurgery (SRS) have gained an increasingly important role to manage tumor residual or recurrence. The role of intracavitary therapies, including antineoplastic drugs or sealed radioactive sources, is predominantly limited to monocystic craniopharyngiomas as secondary therapeutic option. Novel findings in genetic profiling of craniopharyngiomas have unfold new scenarios in the development of targeted therapies based on brand-new biomolecular markers, advancing the hypothesis of introducing neoadjuvant chemotherapy regimens in order to reduce tumor burden prior to resection. Indeed, the rarity of these neoplasms requires a multispecialty approach involving an expert team of endocrinologists, neurosurgeons, neuro-ophthalmologists, neuroradiologists, radiotherapists, and neuro-oncologists, in order to pursue a significant impact on postoperative outcomes and long-term prognosis.

Craniopharyngioma in Children: Long-term Outcomes

Consequences of craniopharyngioma surgery in children

Analysis of Prognostic Factors, Extent of Resection, and Long-Term Outcome of Craniopharyngioma in Adults and Children

Craniopharyngioma in children: trends from a third consecutive single-center cohort study

Advances in the management of craniopharyngioma in children and adults

Does subtotal resection ameliorate hypothalamic morbidity in pediatric craniopharyngioma? A 30-year retrospective cohort study

Visual outcomes after treatment of craniopharyngioma in children: A systematic review

Long‐term sequelae and quality of life after childhood‐onset craniopharyngioma: Results of a Spanish multicenter study

The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature

Postoperative and Long-Term Endocrinologic Complications of Craniopharyngioma

Childhood craniopharyngioma: a retrospective study of children followed in Hôpital Universitaire de Bruxelles

The Diagnosis and Treatment of Craniopharyngioma

Surgical outcomes and follow-up results of 53 pediatric craniopharyngioma cases: a single-center study

Endocrine sequelae after pediatric craniopharyngioma treatment: a single-center retrospective cohort study

Clinical effectiveness of microsurgery for pediatric craniopharyngiomas

Treatment of craniopharyngioma in adults: systematic analysis of a 25-year experience

The Role of Tumor-Associated Hypothalamic Involvement in Surgical Treatment and Long-Term Outcome in Adult Patients with Craniopharyngioma

Craniopharyngiomas: experience and results

[Surgical Treatment of Childhood Craniopharyngioma: Clinical Analysis of 31 Cases].

Craniopharyngioma-An update on metabolic and cognitive complications and new therapy

Craniopharyngioma in Pediatrics and Adults